The preparations of cyclopropanone (1), methylcyclopropanone (2), 2,2-dimethylcyclopropane (3) and tetramethylcyclopropane (4), are described. The spectral properties of these molecules demonstrate unambiguously the ring closed structure for cyclopropanones. The reactions of cyclopropanones with methanol, diazomethane and furan are employed as chemical means of characterization.
Synthesis and rearrangement of [1,1′-bicyclobutyl]-1-ols and spiro[3.4]octan-5-ols: a general access to bicyclo[3.3.0]octenes (hexahydropentalenes)
作者:Klaus Mandelt、Imelda Meyer-Wilmes、Lutz Fitjer
DOI:10.1016/j.tet.2004.09.074
日期:2004.12
generated and added to cyclobutanones to yield mono- to trimethylated [1,1′-bicyclobutyl]-1-ols. Mono- to trimethylated spiro[3.4]octan-5-ols have been prepared from the parent ketone via alkylation and/or addition reactions. Upon treatment with acid, all [1,1′-bicyclobutyl]-1-ols and spiro[3.4]octan-5-ols rearrange to yield a single bicyclo[3.3.0]octene.
Solvolysis of acyclic allenic tosylates shows that the allene group participates strongly to give cyclopropyl ketones and methylenecyclobutanols. Whenever C4 and C5 of the 3-methyl penta-1,2 dien-5-yl system carry different substituents, an apparent exchange of position between them occurs during the cyclisation.
Rearrangements initiated by trimethylsilyl iodide: the facile ring opening of some cyclobutanone derivatives
作者:R.D. Miller、D.R. McKean
DOI:10.1016/s0040-4039(00)92826-0
日期:1980.1
The powerful electrophile trimethylsilyl iodide in the presence of certain catalysts rapidly and cleanly initiates the ring opening of a variety of cyclobutanone derivatives in a highly regioselective fashion yielding ultimately β-iodoketones.
[EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR<br/>[FR] MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA MUCOVISCIDOSE
申请人:VERTEX PHARMA
公开号:WO2022076625A1
公开(公告)日:2022-04-14
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.